US20100174268A1 - Methods of venting, sealing, and dispensing from a medicament container - Google Patents
Methods of venting, sealing, and dispensing from a medicament container Download PDFInfo
- Publication number
- US20100174268A1 US20100174268A1 US12/725,518 US72551810A US2010174268A1 US 20100174268 A1 US20100174268 A1 US 20100174268A1 US 72551810 A US72551810 A US 72551810A US 2010174268 A1 US2010174268 A1 US 2010174268A1
- Authority
- US
- United States
- Prior art keywords
- medicament container
- assembly
- medication
- dispensing
- sealing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/062—Carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M5/2455—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened
- A61M5/2459—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst
- A61M2005/2462—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst by displacing occluding plugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/3257—Semi-automatic sleeve extension, i.e. in which triggering of the sleeve extension requires a deliberate action by the user, e.g. manual release of spring-biased extension means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
- A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
- B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants
Definitions
- the present invention relates to medicament dispensing mechanisms for administering a predetermined dosage of medication.
- the present invention is directed to a medicament dispensing kit or injector used for dispensing a gas sensitive medication (e.g., dihydroergotamine (DHE) and epinephrine) that limits the exposure of the medication to the undesirable gas thereby improving and maintaining the effectiveness of the medication over time.
- a gas sensitive medication e.g., dihydroergotamine (DHE) and epinephrine
- the present invention is also directed to methods of producing a kit that limits exposure of the medication to the undesirable gas (e.g., oxygen).
- the present invention is further directed to a method of storing a medicament in an autoinjector for prolonged periods, and then administering the medicament contained therein.
- Migraine headaches or migraines are generally described as recurrent severe headaches, which can be disabling to the sufferer.
- the duration of migraines can last up to seventy-two (72) hours and can be accompanied by nausea, vomiting and sensitivity to light. It is generally agreed that to successfully treat a migraine, concentrations of an anti-migraine drug in the bloodstream must reach a therapeutic level within a certain time from the onset of the migraine headache in order to be effective in reducing and/or eliminating the migraine headache.
- DHE is effective for the treatment of migraines.
- DHE can be administered intramuscularly, subcutaneously, as a nasal spray, or by other delivery routes.
- DHE degrades when exposed to oxygen.
- the dissolved oxygen content needs to be maintained below at least 2 ppm and more preferably around 0.5 ppm.
- DHE is only available in ampoules for injection using a manual syringe or for use in a nasal spray.
- the ampoules protect the medication from oxygen exposure while stored within the ampoule.
- the use of ampoules requires the user to carryout a number of manipulations prior to use including breaking open the ampoule in order to either draw the medication into a syringe or inserting the opened ampoule into a nasal spray for use.
- Breaking the ampoule may be hazardous because it may produce shards of glass or particles that may mix with the medication and be injected or inhaled by the migraine sufferer. While the ampoule is open and prior to insertion in either the syringe or the nasal sprayer, the DHE is exposed to oxygen, which can lead to degradation of the DHE. Furthermore, DHE is often self administered by the migraine sufferer. Self administration occurs while the sufferer may be experiencing reduced functional and concentration abilities. As such, the sufferer may improperly administer the correct dosage of medication or take an over or under dosage of the medication.
- It is another object of the present invention provide a medicament dispensing kit that provides for the stable storage of a dose of an oxygen sensitive medicament (e.g., DHE or epinephrine).
- an oxygen sensitive medicament e.g., DHE or epinephrine
- the present invention is directed to a medicament dispensing kit for administering a predetermined dose of medication. It is contemplated that the medicament dispensing kit may be used by an individual for self medication and/or treatment. It is further contemplated that the medicament dispensing kit may be used by a health care professional to administer a predetermined dose of medication for a patient.
- each medicament dispensing kit includes a predetermined dose of medication.
- the predetermined dose of medication may include DHE.
- the invention is not limited to the use of DHE; rather, other oxygen sensitive medications including epinephrine or medications that degrade with prolonged exposure to oxygen or other undesirable gases are contemplated for use and are considered to be within the realm of the present invention. It is also contemplated to use the present invention in connection with the storage of medications for the purpose of increasing shelf life. As such, it is contemplated that the present invention may be used in connection with any medicament that is stored for prolonged periods of time.
- the predetermined dose of medication is stored in a medicament container, which was filled in an inert gas environment, which may be provided in an isolator, a tunnel, through a flush of inert gas or a shower of inert gas.
- the medicament container includes a cartridge assembly, which receives the predetermined dose of medication.
- the cartridge assembly may be formed from glass or another suitable material.
- the cartridge assembly has at least one opening formed therein to facilitate filling and dispensing of the dose of medication.
- Each opening contains at least one sealing assembly. It is contemplated that the sealing assemblies may be formed from a rubber or other material that functions as an oxygen absorbing material or an oxygen barrier material.
- one sealing assembly may be formed from an absorbing material and another sealing assembly may be formed from a barrier material. It is further contemplated that one or more of the sealing assemblies may be formed from an oxygen permeable material, whereby the oxygen absorbing material may withdraw oxygen from the system through the seal.
- One of the sealing assemblies is movable within the interior portion of the cartridge assembly in response to activation of a dispensing assembly to facilitate the dispensing of the dose of medication. This sealing assembly is positioned within the interior portion of the container prior to filling with the dose of medication.
- Another sealing assembly is located in another opening in the cartridge assembly after the cartridge assembly is filled with the dose of medication.
- This sealing assembly may include a venting assembly for venting the inert gas from an interior of the cartridge assembly after the predetermined dose of medication has been located therein.
- the inert gas is removed under vacuum pressure. It is also contemplated that it is not necessary to remove all of the inert gas within the cartridge assembly. A partial vacuum may be used to remove a portion of the gas.
- the sealing assembly moves from a sealing position to a dispensing position in response to activation of the dispensing assembly. Alternatively, the sealing assembly may be placed over the neck portion of the cartridge assembly.
- the sealing assembly is punctured in response to actuation of the dispensing assembly and more particularly movement of a needle assembly.
- the sealing assembly is punctured by the needle assembly.
- it is contemplated to provided a diaphragm sealing assembly wherein the diaphragm is ruptured in response to increased pressure by the medicament in response to activation of the
- the medicament container may further include a dispensing element for administering the predetermined dose of medication from the medicament container in response to activation of the dispensing assembly.
- the dispensing element may be a needle for injecting the predetermined dose of medication into the user upon activation of the dispensing assembly.
- the kit in accordance with the present invention further includes a dispensing assembly adapted to receive the medicament container therein.
- the dispensing assembly dispenses the predetermined dose of medication upon activation by a user.
- the dispensing assembly may be an auto-injector, a syringe, a nasal sprayer, a needle free auto-injector or other drug delivery system.
- the dispensing assembly is stored in a sealed package.
- the sealed package forms an oxygen barrier to prevent oxygen from penetrating the dispensing assembly to degrade the dose of medication.
- the sealed package is a high barrier pouch, which prevents oxygen from entering the interior of the package.
- the high barrier pouch is a laminated pouch having several layers.
- one of the layers is preferably a layer of an aluminum foil.
- the high barrier pouch may be located within a rigid secondary packaging such as a rigid container or tube to prevent puncture of the barrier pouch.
- the sealed package may be formed as a rigid container or formed from an oxygen barrier material such as aluminum or a suitable polymer. It is also contemplated that the sealed package may be a thermoformed package or a metal tube.
- An inert gas is flushed through the interior compartment of the sealed package when the dispensing assembly is placed in the package to remove the presence of any oxygen or undesired gas within the compartment.
- a gas absorbing material may be located in the sealed package to absorb any oxygen that may be out gassed from the dispensing assembly. It is contemplated that ascorbic acid, iron powder, borohydride or mordenite/calcium oxide systems or halon gas or equivalent materials may be used as a gas absorbing material. It is also contemplated that a gas absorbing material be omitted from the package. It is also contemplated that the interior compartment of the sealed package may be filled with an inert gas or air. It is further contemplated that the interior compartment may be sealed under vacuum to create a vacuum within the sealed package.
- the present invention is not limited to a single sealed package; rather, it is contemplated that the sealed package may include a plurality of separate sealed interior compartments. Each sealed compartment contains a dispensing assembly having the predetermined dose of medication located therein.
- the present invention is also directed to a method of packaging a predetermined dose of medication.
- the packaging method reduces exposure of the medication to oxygen, which reduces degradation of the medication.
- the method includes providing a predetermined dose of medication, which is placed in a medicament container.
- the filling of the medicament container occurs in an environment containing an inert gas.
- the use of the inert gas e.g., argon, nitrogen, CO 2 or halon
- the interior compartment of the medicament container is purged using the inert gas to eliminate the presence of oxygen.
- the medicament container is then sealed in the inert gas environment, which may be provided by an isolator, a tunnel, through a flush of inert gas or a shower of inert gas.
- a sealing assembly is placed in an opening in the medicament container.
- the sealing assembly is located within the opening such that it is in a venting position to permit the removal of any remaining gas from medicament container. It is also contemplated that a portion of the inert gas may remain within the medicament container.
- a partial vacuum may be created within the container using the inert gas.
- the inert gas is then withdrawn from the medicament container by applying a vacuum to the medicament container.
- the sealing assembly is then seated in the opening to a sealing position, while the medicament container is still subject to the vacuum.
- the sealing assembly may be placed around the neck portion of the cartridge assembly after the inert gas purge.
- the sealing assembly may include a portion that fits within the neck portion and a portion that extends around the neck portion of the cartridge assembly.
- dispensing assembly may be a syringe, an auto-injector, a nasal sprayer, or other suitable means for dispensing the predetermined dosage.
- the loaded dispensing assembly is then located in a package.
- the interior of the package may be flushed with an inert gas to remove any oxygen.
- An oxygen absorbing material is located within the package.
- the oxygen absorbing material may be formed on the wall of the package, inserted as a separate packet within the package, or provided as a powder within the interior of the package, formed as part of one of the components of the drug delivery system (e.g. a component of the autoinjector), located in a compartment within the drug delivery system, or a separate component of the drug delivery system.
- the package may be filled with an inert gas to prevent shrinkage of the pouch created by the absence of air within the pouch.
- the package is designed to limit exposure of the medication to oxygen.
- the packaging and the packaging process are designed to limit oxygen exposure and absorb any oxygen that may be out gassed from the dispensing assembly once located in the package.
- FIG. 1 is a cross sectional schematic view of a medicament dispensing kit in accordance with an embodiment of the present invention
- FIG. 2 is a cross sectional schematic view illustrating the sealing assemblies and the container assembly for the medicament container;
- FIG. 3 is a cross sectional schematic view illustrating the location of the sealing assemblies and the container assembly during the venting operation whereby the inert gas is vented from the interior of the container assembly;
- FIG. 4 is a cross sectional schematic view illustrating the location of the sealing assemblies and the container assembly in the sealed position after the venting operation;
- FIG. 5 is a cross sectional view of the sealing assembly for the medicament container in accordance with the present invention.
- FIG. 6 is a cross sectional view of the medicament container illustrating the position of the sealing assembly in a storage position when the dispenser assembly is located in the sealed package;
- FIG. 7 is a cross sectional view of the medicament container illustrating the position of the sealing assembly upon activation of the dispenser assembly by the user;
- FIG. 8 is a cross sectional view of the medicament container illustrating the position of the sealing assembly in an ejection position whereby the medication is administered to the patient;
- FIG. 9 is a cross sectional view of the medicament container in accordance with another embodiment of the present invention.
- FIG. 10 is a cross sectional view of the medicament container of FIG. 9 located within a syringe
- FIG. 11 is a cross sectional view of the medicament container of FIG. 9 located in an auto-injector
- FIG. 12 is a cross sectional view of the sealing assembly of FIG. 9 ;
- FIG. 13 is a cross sectional view of a medicament dispensing kit having a cartrix type dispensing assembly in accordance with an embodiment of the present invention.
- a medicament dispensing kit 1 is illustrated in FIG. 1 .
- the kit 1 includes a sealed package 10 , a medication dispensing assembly 20 , and a medicament container 30 .
- the kit 1 also includes an oxygen absorbing component 40 .
- the medicament container 30 includes a cartridge assembly or vial 31 having an interior compartment for receiving a predetermined dose of medication.
- the cartridge assembly or vial 31 is preferably formed from glass.
- the present invention is not limited to a cartridge assembly 31 formed from glass; rather, other materials that are non reactive with DHE or other oxygen sensitive medicaments and prevent the passage of oxygen there through are considered to be well within the scope of the present invention.
- the medicament container 30 also includes a pair of sealing assemblies 32 and 33 for sealing the open end portions of the cartridge assembly 31 as shown in FIG. 4 .
- the sealing assemblies 32 and 33 are preferably formed from rubber.
- the sealing assemblies 32 and 33 may be formed from a material (e.g., rubber or other suitable material) that has oxygen barrier capabilities (e.g., West 4405/50 or 4416/50 bromobutyl rubber) or oxygen absorbing capabilities (e.g., Diakyo 777 series rubber or PTFE). It is further contemplated that either of the sealing assemblies 32 and 33 may be formed from an oxygen permeable material to permit the passage of oxygen from the interior of the medicament container 30 to the oxygen or gas absorbing material. It is also contemplated that the medicament container 30 may be formed from an oxygen or gas permeable material to permit the withdrawal of oxygen or other undesirable gas from the interior of the medicament container 30 by the oxygen/gas absorbing material.
- a material e.g., rubber or other suitable material
- oxygen barrier capabilities e.g., West 4405/50 or 4416/50 bromobutyl rubber
- oxygen absorbing capabilities e.g., Diakyo 777 series rubber or PTFE
- either of the sealing assemblies 32 and 33 may be
- a first sealing assembly 32 is positioned in the interior compartment of the cartridge assembly 31 , as shown in FIG. 2 .
- the first sealing assembly 32 is adapted to frictionally engage the inner surface of the cartridge assembly 31 to prevent the medication from passing between the first sealing assembly 32 and the inner surface of the cartridge assembly 31 .
- the first sealing assembly 32 is adapted to be engaged by an actuator element of the dispensing assembly 20 , as shown in FIG. 1 . Under the action of the dispensing assembly 20 , the first sealing assembly 32 slides within the interior compartment of the cartridge assembly 31 towards the second sealing component 33 , as shown in FIGS. 6-8 . The movement of the first sealing assembly 32 pressurizes the medication within the cartridge assembly 31 to dislodge the second sealing component 33 to permit the administering of the medication.
- the medication may be administered through a dispensing element 34 , as shown in FIGS. 1 and 6 - 8 .
- the dispensing element 34 includes a housing 341 that is adapted to engage a neck portion 311 of the cartridge assembly 31 .
- the dispensing element 34 also includes a needle assembly 342 for injecting the medication directly into the bloodstream, skin tissue, or muscle tissue.
- the needle assembly 342 may be used when the dispensing assembly 20 is an auto-injector, a syringe, or an alternative drug delivery system.
- the present invention is not limited to the use of a needle assembly 342 ; rather, the aspirating element may be provided to permit aspiration of the medication such that it can be dispensed through a nasal sprayer, needle free auto-injector, or alternative drug delivery system.
- the second sealing component 33 is illustrated in greater detail in FIG. 5 .
- the second sealing component 33 includes a body portion 331 that is designed to frictionally engage the inner surface of the cartridge assembly 31 adjacent the neck portion 311 .
- the second sealing component 33 further includes one or more venting passageways 332 formed in a portion of the exterior surface of the body portion 331 .
- the venting passageways 332 permit the venting of gases from the interior compartment of cartridge assembly 31 during the filling operation, as shown in FIG. 3 .
- the venting passageways 332 further permit the passage of medication there through during the medication dispensing operation, as shown in FIG. 8 .
- the body portion 331 of the second sealing component 33 includes a plurality of ribs or projections 333 extending from an end portion, as shown in FIG. 5 .
- the ribs 333 are radially spaced around the perimeter of the second sealing component 33 .
- the second sealing component 33 moves from the position illustrated in FIG. 6 to the position illustrated in FIG. 8 whereby the ribs 333 of the second sealing component 33 contact an interior surface of the housing 341 .
- the venting passageways 332 permit the passage of medication into the housing 341 . The medication then travels through the space between the ribs 333 and interior surface of the housing 341 to the needle assembly 342 .
- the space between the ribs 333 and interior surface of the housing 341 ensures a liquid communication path between the cartridge assembly 31 and the needle assembly. This space may also control the size of medication particles traveling through the needle assembly 342 to prevent clogging of the needle assembly 342 .
- the medicament container 30 is adapted to be received within a dispensing assembly 20 .
- the dispensing assembly 20 is an auto-injector, as shown in FIG. 1 .
- the medicament container 30 may be used in a wide variety of single use auto-injectors as disclosed, for example but not limited to, in U.S. Pat. No. 4,031,893 to Kaplan et al., U.S. Pat. No. 5,295,965 to Wilmot et al., U.S. Pat. No. 5,102,393 to Sarnoff et al., and U.S. Pat. No. 5,092,843 to Monroe et al.
- the medicament container 30 may be used in a multi-use auto-injector as disclosed, for example in, U.S. Pat. No. 5,085,642 to Sarnoff et al.
- the disclosure of this patent is specifically incorporated herein by reference.
- the present invention is not limited to an auto-injector; rather other dispensing assemblies including but not limited to prefilled syringes, nasal sprayers, needle free auto-injectors and other medication administering devices are considered to be well within the scope of the present invention.
- the auto-injector 20 illustrated in FIG. 1 includes a housing 21 .
- the medicament container 30 is located within the housing 21 .
- the auto-injector 20 further includes an operating assembly 22 located within the housing 21 .
- the operating assembly 22 includes an actuator arm 221 , which is adapted to engage the first sealing assembly 32 .
- the biased actuator arm 221 moves the first sealing assembly 32 from the storage position illustrated in FIG. 6 through the dispensing position illustrated in FIG. 7 to the position illustrated in FIG. 8 .
- the pressure within the interior compartment of the cartridge assembly 31 causes the second sealing component 33 to move to an extended position, as shown in FIG. 8 , such that the dose of medication can be dispensed through the dispensing element 34 .
- the dispensing assembly 20 and the medicament container 30 are packaged in a sealed package 10 .
- the sealed barrier package 10 prevents oxygen from entering the interior of the package 11 through the package walls 12 .
- the package walls 12 are preferably formed as a laminate containing more than one layer.
- each wall 12 of the package 10 preferably includes a layer of aluminum foil.
- the wall 12 may be formed with three laminate layers including polyethylene terephthalate (PET), aluminum foil and polyethylene (PE).
- PET polyethylene terephthalate
- PE polyethylene
- the wall 12 may be formed with five laminate layers including biaxial nylon, polyvinyl dichloride (PVDC), low density polyethylene (LDPE), aluminum foil, another layer of LDPE and linear, low density polyethylene (LLDPE).
- PVDC polyvinyl dichloride
- LDPE low density polyethylene
- LLDPE linear, low density polyethylene
- the laminated walls 12 form a package 10 having an interior compartment 11 .
- the above-described dispensing assembly 20 containing the medicament container 30 are located within the compartment 11 prior to sealing the package 10 .
- the package 10 can be sealed by any suitable means that would prevent the passage of oxygen into the interior compartment 11 .
- the package 10 may be located in a rigid secondary package 90 . It is also contemplated that the package 10 may be formed as a rigid container (such as for example a can) using aluminum or other suitable oxygen barrier materials. It is further contemplated that the package 10 may be thermoformed or formed as a rigid tube.
- an oxygen absorbing material 40 is located within the interior compartment. Ascorbic acid, iron powder, borohydride or mordenite/calcium oxide systems, or halon gas are all suitable oxygen absorbing materials.
- the oxygen absorbing material may be applied to the interior wall of the walls 12 .
- a package 40 of the material may be located within the package 10 , as shown in FIG. 10 .
- the material may be placed in powder form within the compartment 11 .
- the oxygen absorbing material may take the form of a self adhesive patch or disc 80 sewed to an inner wall of the package 10 .
- one or more of the components of the dispensing assembly 20 may be formed from the oxygen absorbing material. It is also contemplated, but not preferred, that the interior compartment 11 may be evacuated of all gas so that a gas absorbing component is unnecessary.
- Packaging the dispensing assembly 20 into a high barrier laminate package 10 preferable incorporating aluminum foil with an oxygen absorber and preferably an inert gas flush will provide a very good oxygen barrier to prevent ingress of oxygen into the pouch.
- the oxygen absorber will absorb any oxygen that maybe present in the pouch, in the dispensing assembly 20 and the medicament container 30 , dissolved oxygen that may out gas from the assembly 20 and the container 30 and in particular the sealing assemblies 32 and 33 .
- the absorber 40 will act as an oxygen sink to draw any extraneous oxygen out of the container 30 . It is contemplated that a sufficient amount of the oxygen absorber will be provided to absorb any oxygen that permeates in through the seals in the package 10 over the expected lifetime of the product.
- the medicament container 300 includes a cartridge assembly 31 , as discussed above.
- a first sealing assembly 32 is located within the interior of the cartridge assembly 31 .
- the sealing assembly 31 is adapted to engaged by the actuator assembly 51 of a syringe 50 , as shown in FIG. 10 , or the actuator assembly 61 of the auto-injector 60 , as shown in FIG. 11 .
- the medicament container 300 does not include a second assembly 33 that is received in an opening of the cartridge assembly 31 . Instead, a sealing assembly 310 is provided.
- the sealing assembly 310 includes an inner sealing member 320 , which is formed from a rubber material, as described above. As shown in FIG.
- the sealing assembly 310 further includes an outer sealing member 330 formed as a metal cap assembly.
- the outer sealing member has a hole formed therein to permit the passage of the needle assembly 521 or 621 therethrough.
- a foil layer 331 may be provided to cover the hole prior to passage of the needle assembly 521 or 621 therethrough to prevent the passage of oxygen into the inner compartment 11 . It is contemplated that the foil layer 331 may be positioned on the outer surface of the outer sealing member 330 or between the outer sealing member 330 and the inner sealing member 320 .
- the outer sealing member is adapted to be crimped, screw fit or compression fit onto the neck portion of the cartridge assembly 31 .
- the outer sealing member 330 provides an axial seal.
- the inner sealing member 320 provides an inner radial seal in the opening in the neck portion of the cartridge assembly 31 .
- the second sealing assembly 310 is adapted to engage the outer surface and the inner surface of the neck portion of the cartridge assembly 31 , as shown in FIG. 9 .
- the outer sealing member 330 may be formed as a foil sheet that is laminated onto the top surface of the inner sealing member 320 .
- the foil may be pierceable by the needle or an end of the actuator assembly. The foil is not intended to contact the medication. It is also contemplated that a reducing die could be used to push the sealing assembly into the cartridge assembly 31 without the use of vacuum pressure. It is also contemplated that a foil layer may be provided on the surface of the plunger 32 .
- a dispensing element 52 is adapted to engage the outer surface of the cartridge assembly 31 such that the sealing assembly 310 is sandwiched there between, as shown in FIG. 10 .
- the actuator assembly 51 moves the first sealing assembly 32 within the interior compartment of the cartridge assembly 31 .
- the pressure supplied by the user causes the needle assembly 521 to move towards the sealing assembly 310 .
- the sealing assembly 310 contacts an end portion of a needle assembly 521 in the dispensing element 52 , which causes the needle assembly 521 to penetrate the inner sealing member 320 .
- the dose of medication then passes through the needle assembly 521 .
- the needle assembly 521 punctures the seal before the actuator assembly 51 is depressed.
- the diaphragm 600 expands and is ruptured after the actuator assembly has been actuated.
- the present invention may be used in connection with a Hypak® syringe.
- the needle assembly 342 is bonded or attached directly to the end of the cartridge assembly.
- the needle assembly 342 is located within a hole within the cartridge assembly, which preferably formed from glass.
- the housing 341 can be eliminated.
- only one sealing assembly in contact with the medicament is necessary.
- An additional seal may be provided around the outer periphery of the needle assembly.
- a dispensing element 62 is adapted to engage the outer surface of the cartridge assembly 31 such that the sealing assembly 310 is sandwiched there between, as shown in FIG. 11 .
- the actuator assembly 61 moves the first sealing assembly 32 within the interior compartment of the cartridge assembly 31 .
- the cartridge assembly 31 and the sealing assembly 310 move within the dispensing assembly 60 in the direction of the needle assembly 621 in the dispensing element 62 .
- the end portion of the needle assembly 621 located within the dispensing assembly 60 penetrates the sealing assembly 310 such that the medication is then transmitted through the needle assembly 621 into the user.
- the operation of the needle assembly 621 penetrating a sealing assembly 310 is described in greater detail in U.S. Pat.
- the dose of medication then passes through the needle assembly 621 .
- the inner sealing assembly 320 extend into the neck portion of the cartridge assembly 31 to provide a radial seal and increased protection against oxygen penetration. It, however, is contemplated that the size the inner sealing member 320 that projects into the opening of the neck portion may be reduced or eliminated, as shown for example in FIG. 9 . This, however, may result in increased oxygen penetration.
- the packaging method reduces exposure of the medication to oxygen.
- the method includes providing a predetermined dose of medication, which is placed in a medicament container 30 .
- the filling of the medicament container 30 occurs in an environment containing an inert gas.
- the inert gas may be located in an isolator, a tube or tunnel containing a flush of inert gas or a shower of inert gas.
- the use of the inert gas e.g., argon or nitrogen
- the interior compartment of the cartridge assembly 31 is purged using the inert gas to eliminate the presence of oxygen. It is also contemplated that the cartridge assembly 31 may be filled from either open end.
- the cartridge assembly 31 is then sealed in the inert gas environment.
- the sealing assembly 33 is placed in an opening in the cartridge assembly 31 , as shown in FIG. 3 .
- the sealing assembly 33 is located within the opening such that it is in a venting position to permit the removal of any remaining gas from the interior compartment of the cartridge assembly 31 .
- the inert gas is then withdrawn from the cartridge assembly 31 by applying a vacuum. It is not necessary to remove all of the inert gas.
- the sealing assembly 33 is then seated in the opening to a sealing position by the application of pressure to the sealing assembly 33 while the medicament container 30 is still subject to the vacuum. It is also contemplated that a reducing die could be used to push the sealing assembly into the cartridge assembly 31 without the use of vacuum pressure.
- the venting operation is not performed when the sealing assembly 310 is used.
- the medicament container 30 is then placed in a dispensing assembly 20 .
- the medicament container 30 is positioned in the dispensing assembly 20 such that the user can simply activate the operating assembly 22 of dispensing assembly 20 , as shown for example in FIG. 1 , to dispense the predetermined dosage of the medication.
- dispensing assembly 20 may be a syringe, as shown in FIG. 10 , an auto-injector, as shown in FIGS. 1 and 11 , a nasal sprayer or other suitable means for dispensing the predetermined dosage.
- the dispensing assembly 20 may be more tightly sealed to prevent the passage of oxygen or gas if the gas absorbing material is located within the assembly 20 .
- the gas absorbing material 40 is a separate member that is stored within a space within the autoinjector housing 21 , and in gaseous communication with the medicament cartridge assembly. In such embodiment, it may be desirable (though not required) to manufacture components of the dispensing assembly 20 itself substantially impervious to air to shield the gas absorbing material 40 from air. In this embodiment, the outer package 12 can be dispensed with.
- the loaded dispensing assembly 20 is then located in a package 10 .
- the interior of the package 10 is flushed with an inert gas to remove any oxygen. It is not necessary to perform this operation, but it is preferable because it reduces the stress on the oxygen absorbing material thereby permitting the material to Withdraw more oxygen from the components.
- An oxygen absorbing material 40 is located within the package 10 .
- the oxygen absorbing material 40 may be formed on the wall of the package, inserted as a separate packet, as shown in FIG. 1 within the package or powder within the interior of the package or as part of the dispensing assembly 20 .
- the package 10 is designed to limit exposure of the medication to oxygen.
- the packaging 10 and the packaging process are designed to limit oxygen exposure and absorb any oxygen that may be out gassed from the dispensing assembly 20 once located in the package 10 .
- the containers 11 are filled in an argon or inert gas environment, may be inspected and packaged in air as quickly as possible to minimize the exposure of the medicament to oxygen or other undesired gases.
- the inert gas environment may be provided by means of an isolator, a tunnel, through a flush of inert gas or a shower of inert gas
- the above described medicament container, kit and packaging process simplify the use of DHE and other oxygen sensitive medications, while improving the stability of DHE.
- the dispensing assembly 20 provides for standard easier use allowing immediate easy use by the patient without significant manipulation or assembly.
- the dispensing assembly 20 will be user friendly, more convenient & provide better dosing accuracy over an ampoule based system. This is particularly important for the migraine application during patient self-injection when patient's functional and concentration abilities are reduced, their vision maybe impaired & they maybe feeling nausea. It will be apparent to those skilled in the art that various modifications and variations may be made without departing from the scope of the present invention.
- each package 10 may include a plurality of interior compartments 11 that may be separately opened.
- Each compartment may contain a dispensing assembly 20 and a medicament container 30 .
- one compartment may contain a dispensing assembly and a medicament container, while the remaining compartments contain additional doses of medication in medicament containers 30 that are loaded into the dispensing assembly by the patient or health care provider when opened.
Abstract
Description
- This is a continuation of U.S. patent application Ser. No. 10/285,692, filed Nov. 1, 2002, now U.S. Pat. No. ______, which claims the benefit of U.S. Provisional Application No. 60/330,945, filed Nov. 2, 2001, and U.S. Provisional Application No. 60/350,972, filed Jan. 25, 2002. These disclosures are each incorporated herein in their entirety by reference.
- The present invention relates to medicament dispensing mechanisms for administering a predetermined dosage of medication. In one embodiment, the present invention is directed to a medicament dispensing kit or injector used for dispensing a gas sensitive medication (e.g., dihydroergotamine (DHE) and epinephrine) that limits the exposure of the medication to the undesirable gas thereby improving and maintaining the effectiveness of the medication over time. The present invention is also directed to methods of producing a kit that limits exposure of the medication to the undesirable gas (e.g., oxygen). The present invention is further directed to a method of storing a medicament in an autoinjector for prolonged periods, and then administering the medicament contained therein.
- Migraine headaches or migraines are generally described as recurrent severe headaches, which can be disabling to the sufferer. The duration of migraines can last up to seventy-two (72) hours and can be accompanied by nausea, vomiting and sensitivity to light. It is generally agreed that to successfully treat a migraine, concentrations of an anti-migraine drug in the bloodstream must reach a therapeutic level within a certain time from the onset of the migraine headache in order to be effective in reducing and/or eliminating the migraine headache. DHE is effective for the treatment of migraines. DHE can be administered intramuscularly, subcutaneously, as a nasal spray, or by other delivery routes.
- DHE (as with other medicaments), however, degrades when exposed to oxygen. To be effective, the dissolved oxygen content needs to be maintained below at least 2 ppm and more preferably around 0.5 ppm. At present, DHE is only available in ampoules for injection using a manual syringe or for use in a nasal spray. The ampoules protect the medication from oxygen exposure while stored within the ampoule. The use of ampoules, however, requires the user to carryout a number of manipulations prior to use including breaking open the ampoule in order to either draw the medication into a syringe or inserting the opened ampoule into a nasal spray for use. Breaking the ampoule may be hazardous because it may produce shards of glass or particles that may mix with the medication and be injected or inhaled by the migraine sufferer. While the ampoule is open and prior to insertion in either the syringe or the nasal sprayer, the DHE is exposed to oxygen, which can lead to degradation of the DHE. Furthermore, DHE is often self administered by the migraine sufferer. Self administration occurs while the sufferer may be experiencing reduced functional and concentration abilities. As such, the sufferer may improperly administer the correct dosage of medication or take an over or under dosage of the medication.
- There is a need for a safe and effective method of storing and administering medicaments, such as DHE, that protects against oxygen degradation and allows a migraine sufferer to self administer a predetermined dosage of medication.
- It is therefore an object of the present invention to provide a packaging system for medication that minimizes exposure to oxygen while permitting easy self administering.
- It is another object of the present invention to provide a packaging system for medication that limits degradation of the medication.
- It is another object of the present invention provide a medicament dispensing kit that provides for the stable storage of a dose of an oxygen sensitive medicament (e.g., DHE or epinephrine).
- It is another object of the present invention to provide a medicament dispensing kit that minimizes the exposure of a dose of DHE to oxygen.
- It is another object of the present invention to provide a medicament dispensing assembly that does not require the use of an ampoule to store the medication.
- It is another object of the present invention to provide a single use medicament dispensing kit that enables a user to self administer a dose of medication.
- It is yet another object of the present invention to provide a packaging assembly that stores a single dose of medication in a protective environment.
- It is yet another object of the present invention to provide a packaging system that extends the shelf life of the medicament.
- It is another object of the present invention to provide secondary packaging to prevent puncturing or damage to the oxygen barrier.
- Additional objects and advantages of the invention are set forth, in part, in the description which follows, and, in part, will be apparent to one of ordinary skill in the art from the description and/or practice of the invention.
- In response to the foregoing challenges, applicants have developed an innovative medicament container, medicament dispensing kit and packaging process that minimizes exposure of the medication to oxygen to prevent degradation of the medication.
- The present invention is directed to a medicament dispensing kit for administering a predetermined dose of medication. It is contemplated that the medicament dispensing kit may be used by an individual for self medication and/or treatment. It is further contemplated that the medicament dispensing kit may be used by a health care professional to administer a predetermined dose of medication for a patient. In accordance with the present invention, each medicament dispensing kit includes a predetermined dose of medication. The predetermined dose of medication may include DHE. The invention, however, is not limited to the use of DHE; rather, other oxygen sensitive medications including epinephrine or medications that degrade with prolonged exposure to oxygen or other undesirable gases are contemplated for use and are considered to be within the realm of the present invention. It is also contemplated to use the present invention in connection with the storage of medications for the purpose of increasing shelf life. As such, it is contemplated that the present invention may be used in connection with any medicament that is stored for prolonged periods of time.
- In accordance with the present invention, the predetermined dose of medication is stored in a medicament container, which was filled in an inert gas environment, which may be provided in an isolator, a tunnel, through a flush of inert gas or a shower of inert gas. The medicament container includes a cartridge assembly, which receives the predetermined dose of medication. The cartridge assembly may be formed from glass or another suitable material. The cartridge assembly has at least one opening formed therein to facilitate filling and dispensing of the dose of medication. Each opening contains at least one sealing assembly. It is contemplated that the sealing assemblies may be formed from a rubber or other material that functions as an oxygen absorbing material or an oxygen barrier material. It is also contemplated that one sealing assembly may be formed from an absorbing material and another sealing assembly may be formed from a barrier material. It is further contemplated that one or more of the sealing assemblies may be formed from an oxygen permeable material, whereby the oxygen absorbing material may withdraw oxygen from the system through the seal. One of the sealing assemblies is movable within the interior portion of the cartridge assembly in response to activation of a dispensing assembly to facilitate the dispensing of the dose of medication. This sealing assembly is positioned within the interior portion of the container prior to filling with the dose of medication.
- Another sealing assembly is located in another opening in the cartridge assembly after the cartridge assembly is filled with the dose of medication. This sealing assembly may include a venting assembly for venting the inert gas from an interior of the cartridge assembly after the predetermined dose of medication has been located therein. The inert gas is removed under vacuum pressure. It is also contemplated that it is not necessary to remove all of the inert gas within the cartridge assembly. A partial vacuum may be used to remove a portion of the gas. The sealing assembly moves from a sealing position to a dispensing position in response to activation of the dispensing assembly. Alternatively, the sealing assembly may be placed over the neck portion of the cartridge assembly. The sealing assembly is punctured in response to actuation of the dispensing assembly and more particularly movement of a needle assembly. The sealing assembly is punctured by the needle assembly. Alternatively, it is contemplated to provided a diaphragm sealing assembly, wherein the diaphragm is ruptured in response to increased pressure by the medicament in response to activation of the dispensing assembly.
- In accordance with the present invention, the medicament container may further include a dispensing element for administering the predetermined dose of medication from the medicament container in response to activation of the dispensing assembly. In the case of an auto-injector or a syringe, the dispensing element may be a needle for injecting the predetermined dose of medication into the user upon activation of the dispensing assembly.
- The kit in accordance with the present invention further includes a dispensing assembly adapted to receive the medicament container therein. The dispensing assembly dispenses the predetermined dose of medication upon activation by a user. The dispensing assembly may be an auto-injector, a syringe, a nasal sprayer, a needle free auto-injector or other drug delivery system. The dispensing assembly is stored in a sealed package. The sealed package forms an oxygen barrier to prevent oxygen from penetrating the dispensing assembly to degrade the dose of medication. In accordance with the present invention, the sealed package is a high barrier pouch, which prevents oxygen from entering the interior of the package. Preferably, the high barrier pouch is a laminated pouch having several layers. Furthermore, one of the layers is preferably a layer of an aluminum foil. It is contemplated that the high barrier pouch may be located within a rigid secondary packaging such as a rigid container or tube to prevent puncture of the barrier pouch. It is also contemplated that the sealed package may be formed as a rigid container or formed from an oxygen barrier material such as aluminum or a suitable polymer. It is also contemplated that the sealed package may be a thermoformed package or a metal tube.
- An inert gas is flushed through the interior compartment of the sealed package when the dispensing assembly is placed in the package to remove the presence of any oxygen or undesired gas within the compartment. A gas absorbing material may be located in the sealed package to absorb any oxygen that may be out gassed from the dispensing assembly. It is contemplated that ascorbic acid, iron powder, borohydride or mordenite/calcium oxide systems or halon gas or equivalent materials may be used as a gas absorbing material. It is also contemplated that a gas absorbing material be omitted from the package. It is also contemplated that the interior compartment of the sealed package may be filled with an inert gas or air. It is further contemplated that the interior compartment may be sealed under vacuum to create a vacuum within the sealed package. This will limit the amount of air or gas within the sealed package at the onset. It is contemplated that a certain amount of air will permeate the seal of the package and be absorbed by the absorbing material. The presence of the vacuum will increase the useful life of the gas absorbing material by limiting the exposure of the material to the undesired gas at the onset.
- The present invention is not limited to a single sealed package; rather, it is contemplated that the sealed package may include a plurality of separate sealed interior compartments. Each sealed compartment contains a dispensing assembly having the predetermined dose of medication located therein.
- The present invention is also directed to a method of packaging a predetermined dose of medication. The packaging method reduces exposure of the medication to oxygen, which reduces degradation of the medication. The method includes providing a predetermined dose of medication, which is placed in a medicament container. The filling of the medicament container occurs in an environment containing an inert gas. The use of the inert gas (e.g., argon, nitrogen, CO2 or halon) limits oxygen exposure. During the filling operation, the interior compartment of the medicament container is purged using the inert gas to eliminate the presence of oxygen.
- The medicament container is then sealed in the inert gas environment, which may be provided by an isolator, a tunnel, through a flush of inert gas or a shower of inert gas. During the sealing operation, a sealing assembly is placed in an opening in the medicament container. The sealing assembly is located within the opening such that it is in a venting position to permit the removal of any remaining gas from medicament container. It is also contemplated that a portion of the inert gas may remain within the medicament container. A partial vacuum may be created within the container using the inert gas. The inert gas is then withdrawn from the medicament container by applying a vacuum to the medicament container. It is also contemplated that all of the inert gas, a portion of the inert gas, or none of the inert gas is removed from the medicament container. The sealing assembly is then seated in the opening to a sealing position, while the medicament container is still subject to the vacuum. Alternatively, the sealing assembly may be placed around the neck portion of the cartridge assembly after the inert gas purge. The sealing assembly may include a portion that fits within the neck portion and a portion that extends around the neck portion of the cartridge assembly.
- The medicament container is then placed in a dispensing assembly. The medicament container is positioned in the dispensing assembly such that the user can simply activate the dispensing assembly to dispense the predetermined dosage of the medication. As discussed above, it is contemplated that dispensing assembly may be a syringe, an auto-injector, a nasal sprayer, or other suitable means for dispensing the predetermined dosage.
- The loaded dispensing assembly is then located in a package. Prior to and during the locating of the dispensing assembly in the package, the interior of the package may be flushed with an inert gas to remove any oxygen. An oxygen absorbing material is located within the package. The oxygen absorbing material may be formed on the wall of the package, inserted as a separate packet within the package, or provided as a powder within the interior of the package, formed as part of one of the components of the drug delivery system (e.g. a component of the autoinjector), located in a compartment within the drug delivery system, or a separate component of the drug delivery system. The package may be filled with an inert gas to prevent shrinkage of the pouch created by the absence of air within the pouch. As discussed above, the package is designed to limit exposure of the medication to oxygen. Furthermore, the packaging and the packaging process are designed to limit oxygen exposure and absorb any oxygen that may be out gassed from the dispensing assembly once located in the package.
- The invention will be described in conjunction with the following drawing in which like reference numerals designate like elements and wherein:
-
FIG. 1 is a cross sectional schematic view of a medicament dispensing kit in accordance with an embodiment of the present invention; -
FIG. 2 is a cross sectional schematic view illustrating the sealing assemblies and the container assembly for the medicament container; -
FIG. 3 is a cross sectional schematic view illustrating the location of the sealing assemblies and the container assembly during the venting operation whereby the inert gas is vented from the interior of the container assembly; -
FIG. 4 is a cross sectional schematic view illustrating the location of the sealing assemblies and the container assembly in the sealed position after the venting operation; -
FIG. 5 is a cross sectional view of the sealing assembly for the medicament container in accordance with the present invention; -
FIG. 6 is a cross sectional view of the medicament container illustrating the position of the sealing assembly in a storage position when the dispenser assembly is located in the sealed package; -
FIG. 7 is a cross sectional view of the medicament container illustrating the position of the sealing assembly upon activation of the dispenser assembly by the user; -
FIG. 8 is a cross sectional view of the medicament container illustrating the position of the sealing assembly in an ejection position whereby the medication is administered to the patient; -
FIG. 9 is a cross sectional view of the medicament container in accordance with another embodiment of the present invention; -
FIG. 10 is a cross sectional view of the medicament container ofFIG. 9 located within a syringe; -
FIG. 11 is a cross sectional view of the medicament container ofFIG. 9 located in an auto-injector; -
FIG. 12 is a cross sectional view of the sealing assembly ofFIG. 9 ; and -
FIG. 13 is a cross sectional view of a medicament dispensing kit having a cartrix type dispensing assembly in accordance with an embodiment of the present invention. - A
medicament dispensing kit 1 is illustrated inFIG. 1 . Thekit 1 includes a sealedpackage 10, amedication dispensing assembly 20, and amedicament container 30. Thekit 1 also includes anoxygen absorbing component 40. - The
medicament container 30 will now be described in greater detail in connection withFIGS. 2-8 . Themedicament container 30 includes a cartridge assembly orvial 31 having an interior compartment for receiving a predetermined dose of medication. The cartridge assembly orvial 31 is preferably formed from glass. The present invention, however, is not limited to acartridge assembly 31 formed from glass; rather, other materials that are non reactive with DHE or other oxygen sensitive medicaments and prevent the passage of oxygen there through are considered to be well within the scope of the present invention. Themedicament container 30 also includes a pair of sealingassemblies cartridge assembly 31 as shown inFIG. 4 . The sealingassemblies sealing assemblies sealing assemblies medicament container 30 to the oxygen or gas absorbing material. It is also contemplated that themedicament container 30 may be formed from an oxygen or gas permeable material to permit the withdrawal of oxygen or other undesirable gas from the interior of themedicament container 30 by the oxygen/gas absorbing material. - A
first sealing assembly 32 is positioned in the interior compartment of thecartridge assembly 31, as shown inFIG. 2 . Thefirst sealing assembly 32 is adapted to frictionally engage the inner surface of thecartridge assembly 31 to prevent the medication from passing between the first sealingassembly 32 and the inner surface of thecartridge assembly 31. Thefirst sealing assembly 32 is adapted to be engaged by an actuator element of the dispensingassembly 20, as shown inFIG. 1 . Under the action of the dispensingassembly 20, the first sealingassembly 32 slides within the interior compartment of thecartridge assembly 31 towards thesecond sealing component 33, as shown inFIGS. 6-8 . The movement of the first sealingassembly 32 pressurizes the medication within thecartridge assembly 31 to dislodge thesecond sealing component 33 to permit the administering of the medication. The medication may be administered through a dispensingelement 34, as shown in FIGS. 1 and 6-8. The dispensingelement 34 includes ahousing 341 that is adapted to engage a neck portion 311 of thecartridge assembly 31. The dispensingelement 34 also includes aneedle assembly 342 for injecting the medication directly into the bloodstream, skin tissue, or muscle tissue. Theneedle assembly 342 may be used when the dispensingassembly 20 is an auto-injector, a syringe, or an alternative drug delivery system. The present invention, however, is not limited to the use of aneedle assembly 342; rather, the aspirating element may be provided to permit aspiration of the medication such that it can be dispensed through a nasal sprayer, needle free auto-injector, or alternative drug delivery system. - The
second sealing component 33 is illustrated in greater detail inFIG. 5 . Like the first sealingassembly 32, thesecond sealing component 33 includes abody portion 331 that is designed to frictionally engage the inner surface of thecartridge assembly 31 adjacent the neck portion 311. Thesecond sealing component 33 further includes one ormore venting passageways 332 formed in a portion of the exterior surface of thebody portion 331. As described in greater detail below, the ventingpassageways 332 permit the venting of gases from the interior compartment ofcartridge assembly 31 during the filling operation, as shown inFIG. 3 . The ventingpassageways 332 further permit the passage of medication there through during the medication dispensing operation, as shown inFIG. 8 . Thebody portion 331 of thesecond sealing component 33 includes a plurality of ribs orprojections 333 extending from an end portion, as shown inFIG. 5 . Theribs 333 are radially spaced around the perimeter of thesecond sealing component 33. During the dispensing operation, thesecond sealing component 33 moves from the position illustrated inFIG. 6 to the position illustrated inFIG. 8 whereby theribs 333 of thesecond sealing component 33 contact an interior surface of thehousing 341. The ventingpassageways 332 permit the passage of medication into thehousing 341. The medication then travels through the space between theribs 333 and interior surface of thehousing 341 to theneedle assembly 342. The space between theribs 333 and interior surface of thehousing 341 ensures a liquid communication path between thecartridge assembly 31 and the needle assembly. This space may also control the size of medication particles traveling through theneedle assembly 342 to prevent clogging of theneedle assembly 342. - The
medicament container 30 is adapted to be received within a dispensingassembly 20. In accordance with one embodiment of the present invention, the dispensingassembly 20 is an auto-injector, as shown inFIG. 1 . It is contemplated that themedicament container 30 may be used in a wide variety of single use auto-injectors as disclosed, for example but not limited to, in U.S. Pat. No. 4,031,893 to Kaplan et al., U.S. Pat. No. 5,295,965 to Wilmot et al., U.S. Pat. No. 5,102,393 to Sarnoff et al., and U.S. Pat. No. 5,092,843 to Monroe et al. The disclosures of each of these patents are specifically incorporated herein by reference. It is also contemplated that themedicament container 30 may be used in a multi-use auto-injector as disclosed, for example in, U.S. Pat. No. 5,085,642 to Sarnoff et al. The disclosure of this patent is specifically incorporated herein by reference. The present invention, however, is not limited to an auto-injector; rather other dispensing assemblies including but not limited to prefilled syringes, nasal sprayers, needle free auto-injectors and other medication administering devices are considered to be well within the scope of the present invention. - The auto-
injector 20 illustrated inFIG. 1 includes ahousing 21. Themedicament container 30 is located within thehousing 21. The auto-injector 20 further includes an operatingassembly 22 located within thehousing 21. The operatingassembly 22 includes anactuator arm 221, which is adapted to engage the first sealingassembly 32. Upon actuation of the operatingassembly 22, thebiased actuator arm 221 moves the first sealingassembly 32 from the storage position illustrated inFIG. 6 through the dispensing position illustrated inFIG. 7 to the position illustrated inFIG. 8 . The pressure within the interior compartment of thecartridge assembly 31 causes thesecond sealing component 33 to move to an extended position, as shown inFIG. 8 , such that the dose of medication can be dispensed through the dispensingelement 34. - The dispensing
assembly 20 and themedicament container 30 are packaged in a sealedpackage 10. The sealedbarrier package 10 prevents oxygen from entering the interior of thepackage 11 through thepackage walls 12. Thepackage walls 12 are preferably formed as a laminate containing more than one layer. For example, eachwall 12 of thepackage 10 preferably includes a layer of aluminum foil. Thewall 12 may be formed with three laminate layers including polyethylene terephthalate (PET), aluminum foil and polyethylene (PE). Alternatively, thewall 12 may be formed with five laminate layers including biaxial nylon, polyvinyl dichloride (PVDC), low density polyethylene (LDPE), aluminum foil, another layer of LDPE and linear, low density polyethylene (LLDPE). The present invention is not limited to the above-described laminated layers. Various combinations of these materials are possible and are contemplated to be within the scope of the present invention provided these combinations provide a barrier to oxygen penetration. Thelaminated walls 12 form apackage 10 having aninterior compartment 11. The above-describeddispensing assembly 20 containing themedicament container 30 are located within thecompartment 11 prior to sealing thepackage 10. Thepackage 10 can be sealed by any suitable means that would prevent the passage of oxygen into theinterior compartment 11. To protect thepackage 10 from inadvertent rupture, thepackage 10 may be located in a rigidsecondary package 90. It is also contemplated that thepackage 10 may be formed as a rigid container (such as for example a can) using aluminum or other suitable oxygen barrier materials. It is further contemplated that thepackage 10 may be thermoformed or formed as a rigid tube. - To absorb any oxygen that may be present in the
interior compartment 11, that may infiltrate thepackage 10 at the seal between, for example, the laminate layers or that may be out gassed from the dispensingassembly 20, anoxygen absorbing material 40 is located within the interior compartment. Ascorbic acid, iron powder, borohydride or mordenite/calcium oxide systems, or halon gas are all suitable oxygen absorbing materials. The oxygen absorbing material may be applied to the interior wall of thewalls 12. Apackage 40 of the material may be located within thepackage 10, as shown inFIG. 10 . Alternatively, the material may be placed in powder form within thecompartment 11. The oxygen absorbing material may take the form of a self adhesive patch ordisc 80 sewed to an inner wall of thepackage 10. It is also contemplated that one or more of the components of the dispensingassembly 20 may be formed from the oxygen absorbing material. It is also contemplated, but not preferred, that theinterior compartment 11 may be evacuated of all gas so that a gas absorbing component is unnecessary. - Packaging the dispensing
assembly 20 into a highbarrier laminate package 10 preferable incorporating aluminum foil with an oxygen absorber and preferably an inert gas flush will provide a very good oxygen barrier to prevent ingress of oxygen into the pouch. The oxygen absorber will absorb any oxygen that maybe present in the pouch, in the dispensingassembly 20 and themedicament container 30, dissolved oxygen that may out gas from theassembly 20 and thecontainer 30 and in particular the sealingassemblies absorber 40 will act as an oxygen sink to draw any extraneous oxygen out of thecontainer 30. It is contemplated that a sufficient amount of the oxygen absorber will be provided to absorb any oxygen that permeates in through the seals in thepackage 10 over the expected lifetime of the product. - A variation of the
medicament container 30 will be described in connection withFIG. 9 . Themedicament container 300 includes acartridge assembly 31, as discussed above. Afirst sealing assembly 32 is located within the interior of thecartridge assembly 31. The sealingassembly 31 is adapted to engaged by theactuator assembly 51 of asyringe 50, as shown inFIG. 10 , or theactuator assembly 61 of the auto-injector 60, as shown inFIG. 11 . Themedicament container 300 does not include asecond assembly 33 that is received in an opening of thecartridge assembly 31. Instead, a sealingassembly 310 is provided. The sealingassembly 310 includes aninner sealing member 320, which is formed from a rubber material, as described above. As shown inFIG. 12 , the sealingassembly 310 further includes anouter sealing member 330 formed as a metal cap assembly. The outer sealing member has a hole formed therein to permit the passage of theneedle assembly foil layer 331 may be provided to cover the hole prior to passage of theneedle assembly inner compartment 11. It is contemplated that thefoil layer 331 may be positioned on the outer surface of the outer sealingmember 330 or between the outer sealingmember 330 and theinner sealing member 320. The outer sealing member is adapted to be crimped, screw fit or compression fit onto the neck portion of thecartridge assembly 31. Theouter sealing member 330 provides an axial seal. Theinner sealing member 320 provides an inner radial seal in the opening in the neck portion of thecartridge assembly 31. Thesecond sealing assembly 310 is adapted to engage the outer surface and the inner surface of the neck portion of thecartridge assembly 31, as shown inFIG. 9 . Theouter sealing member 330 may be formed as a foil sheet that is laminated onto the top surface of theinner sealing member 320. The foil may be pierceable by the needle or an end of the actuator assembly. The foil is not intended to contact the medication. It is also contemplated that a reducing die could be used to push the sealing assembly into thecartridge assembly 31 without the use of vacuum pressure. It is also contemplated that a foil layer may be provided on the surface of theplunger 32. - A dispensing
element 52 is adapted to engage the outer surface of thecartridge assembly 31 such that the sealingassembly 310 is sandwiched there between, as shown in FIG. 10. During operation, theactuator assembly 51 moves the first sealingassembly 32 within the interior compartment of thecartridge assembly 31. The pressure supplied by the user causes theneedle assembly 521 to move towards the sealingassembly 310. In response, the sealingassembly 310 contacts an end portion of aneedle assembly 521 in the dispensingelement 52, which causes theneedle assembly 521 to penetrate theinner sealing member 320. The dose of medication then passes through theneedle assembly 521. For a syringe type dispensing element, theneedle assembly 521 punctures the seal before theactuator assembly 51 is depressed. For a cartrix type dispensing assembly illustrated inFIG. 13 , thediaphragm 600 expands and is ruptured after the actuator assembly has been actuated. - It is also contemplated that the present invention may be used in connection with a Hypak® syringe. With this arrangement, the
needle assembly 342 is bonded or attached directly to the end of the cartridge assembly. Theneedle assembly 342 is located within a hole within the cartridge assembly, which preferably formed from glass. As such, thehousing 341 can be eliminated. Furthermore, only one sealing assembly in contact with the medicament is necessary. An additional seal may be provided around the outer periphery of the needle assembly. - A dispensing
element 62 is adapted to engage the outer surface of thecartridge assembly 31 such that the sealingassembly 310 is sandwiched there between, as shown inFIG. 11 . During operation, theactuator assembly 61 moves the first sealingassembly 32 within the interior compartment of thecartridge assembly 31. In response, thecartridge assembly 31 and the sealingassembly 310 move within the dispensingassembly 60 in the direction of theneedle assembly 621 in the dispensingelement 62. After injection of theneedle assembly 621 into the user, the end portion of theneedle assembly 621 located within the dispensingassembly 60 penetrates the sealingassembly 310 such that the medication is then transmitted through theneedle assembly 621 into the user. The operation of theneedle assembly 621 penetrating a sealingassembly 310 is described in greater detail in U.S. Pat. No. 6,210,369 to Wilmot et al., the disclosure of which is hereby specifically incorporated herein by reference. The dose of medication then passes through theneedle assembly 621. It is preferably that theinner sealing assembly 320 extend into the neck portion of thecartridge assembly 31 to provide a radial seal and increased protection against oxygen penetration. It, however, is contemplated that the size theinner sealing member 320 that projects into the opening of the neck portion may be reduced or eliminated, as shown for example inFIG. 9 . This, however, may result in increased oxygen penetration. - The packaging process will now be described. The packaging method reduces exposure of the medication to oxygen. Thus, reducing degradation of the medication. The method includes providing a predetermined dose of medication, which is placed in a
medicament container 30. The filling of themedicament container 30 occurs in an environment containing an inert gas. The inert gas may be located in an isolator, a tube or tunnel containing a flush of inert gas or a shower of inert gas. The use of the inert gas (e.g., argon or nitrogen), which is heavier than oxygen, reduces oxygen exposure. During the filling operation, the interior compartment of thecartridge assembly 31 is purged using the inert gas to eliminate the presence of oxygen. It is also contemplated that thecartridge assembly 31 may be filled from either open end. - The
cartridge assembly 31 is then sealed in the inert gas environment. During the sealing operation, the sealingassembly 33 is placed in an opening in thecartridge assembly 31, as shown inFIG. 3 . The sealingassembly 33 is located within the opening such that it is in a venting position to permit the removal of any remaining gas from the interior compartment of thecartridge assembly 31. The inert gas is then withdrawn from thecartridge assembly 31 by applying a vacuum. It is not necessary to remove all of the inert gas. The sealingassembly 33 is then seated in the opening to a sealing position by the application of pressure to the sealingassembly 33 while themedicament container 30 is still subject to the vacuum. It is also contemplated that a reducing die could be used to push the sealing assembly into thecartridge assembly 31 without the use of vacuum pressure. The venting operation is not performed when the sealingassembly 310 is used. - The
medicament container 30 is then placed in a dispensingassembly 20. Themedicament container 30 is positioned in the dispensingassembly 20 such that the user can simply activate the operatingassembly 22 of dispensingassembly 20, as shown for example inFIG. 1 , to dispense the predetermined dosage of the medication. As discussed above, it is contemplated that dispensingassembly 20 may be a syringe, as shown inFIG. 10 , an auto-injector, as shown inFIGS. 1 and 11 , a nasal sprayer or other suitable means for dispensing the predetermined dosage. It is also contemplated that the dispensingassembly 20 may be more tightly sealed to prevent the passage of oxygen or gas if the gas absorbing material is located within theassembly 20. - In one embodiment, the
gas absorbing material 40 is a separate member that is stored within a space within theautoinjector housing 21, and in gaseous communication with the medicament cartridge assembly. In such embodiment, it may be desirable (though not required) to manufacture components of the dispensingassembly 20 itself substantially impervious to air to shield thegas absorbing material 40 from air. In this embodiment, theouter package 12 can be dispensed with. - The loaded dispensing
assembly 20 is then located in apackage 10. Prior to and during the locating of the dispensingassembly 20 in thepackage 10, the interior of thepackage 10 is flushed with an inert gas to remove any oxygen. It is not necessary to perform this operation, but it is preferable because it reduces the stress on the oxygen absorbing material thereby permitting the material to Withdraw more oxygen from the components. Anoxygen absorbing material 40 is located within thepackage 10. Theoxygen absorbing material 40 may be formed on the wall of the package, inserted as a separate packet, as shown inFIG. 1 within the package or powder within the interior of the package or as part of the dispensingassembly 20. As discussed above, thepackage 10 is designed to limit exposure of the medication to oxygen. Furthermore, thepackaging 10 and the packaging process are designed to limit oxygen exposure and absorb any oxygen that may be out gassed from the dispensingassembly 20 once located in thepackage 10. Thecontainers 11 are filled in an argon or inert gas environment, may be inspected and packaged in air as quickly as possible to minimize the exposure of the medicament to oxygen or other undesired gases. The inert gas environment may be provided by means of an isolator, a tunnel, through a flush of inert gas or a shower of inert gas - The above described medicament container, kit and packaging process simplify the use of DHE and other oxygen sensitive medications, while improving the stability of DHE. Furthermore, the dispensing
assembly 20 provides for standard easier use allowing immediate easy use by the patient without significant manipulation or assembly. The dispensingassembly 20 will be user friendly, more convenient & provide better dosing accuracy over an ampoule based system. This is particularly important for the migraine application during patient self-injection when patient's functional and concentration abilities are reduced, their vision maybe impaired & they maybe feeling nausea. It will be apparent to those skilled in the art that various modifications and variations may be made without departing from the scope of the present invention. Although the present invention has been described in connection with the treatment of migraines using DHE, it is contemplated that various medications including epinephrine may be employed while practicing the present invention. Furthermore, asingle package 10 has been described. It is contemplated, however, that eachpackage 10 may include a plurality ofinterior compartments 11 that may be separately opened. Each compartment may contain a dispensingassembly 20 and amedicament container 30. Alternatively, one compartment may contain a dispensing assembly and a medicament container, while the remaining compartments contain additional doses of medication inmedicament containers 30 that are loaded into the dispensing assembly by the patient or health care provider when opened. Thus, it is intended that the present invention covers the modifications and variations of the invention, provided they come within the scope of the appended claims and their equivalents.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/725,518 US20100174268A1 (en) | 2001-11-02 | 2010-03-17 | Methods of venting, sealing, and dispensing from a medicament container |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33094501P | 2001-11-02 | 2001-11-02 | |
US35097202P | 2002-01-25 | 2002-01-25 | |
US10/285,692 US7708719B2 (en) | 2001-11-02 | 2002-11-01 | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
US12/725,518 US20100174268A1 (en) | 2001-11-02 | 2010-03-17 | Methods of venting, sealing, and dispensing from a medicament container |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/285,692 Continuation US7708719B2 (en) | 2001-11-02 | 2002-11-01 | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100174268A1 true US20100174268A1 (en) | 2010-07-08 |
Family
ID=26987519
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/285,692 Active 2028-09-04 US7708719B2 (en) | 2001-11-02 | 2002-11-01 | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
US12/725,518 Abandoned US20100174268A1 (en) | 2001-11-02 | 2010-03-17 | Methods of venting, sealing, and dispensing from a medicament container |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/285,692 Active 2028-09-04 US7708719B2 (en) | 2001-11-02 | 2002-11-01 | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same |
Country Status (10)
Country | Link |
---|---|
US (2) | US7708719B2 (en) |
EP (1) | EP1455864A2 (en) |
JP (1) | JP2005508231A (en) |
KR (1) | KR20050042210A (en) |
CN (1) | CN1607968A (en) |
AU (2) | AU2002348148B2 (en) |
CA (1) | CA2465436A1 (en) |
IL (1) | IL161682A0 (en) |
MX (1) | MXPA04004162A (en) |
WO (1) | WO2003039632A2 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8616879B2 (en) | 2011-03-22 | 2013-12-31 | Centrix, Inc. | Capsule and delivery tip with transition portion for dispensing viscous reactive dental materials |
US8945063B2 (en) | 2009-03-20 | 2015-02-03 | Antares Pharma, Inc. | Hazardous agent injection system |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
US9180259B2 (en) | 2005-01-24 | 2015-11-10 | Antares Pharma, Inc. | Prefilled syringe jet injector |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US9333288B2 (en) | 2011-09-30 | 2016-05-10 | Becton Dickinson France, S.A.S. | Attachable plunger rod and associated packaging |
US9333309B2 (en) | 2002-02-11 | 2016-05-10 | Antares Pharma, Inc. | Intradermal injector |
US9364611B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US20160199257A1 (en) * | 2010-12-29 | 2016-07-14 | Cardinal Health 414, Llc | Closed vial fill system for aseptic dispensing |
US9393367B2 (en) | 2013-03-12 | 2016-07-19 | Antares Pharma, Inc. | Prefilled syringes and kits thereof |
US9446195B2 (en) | 2011-07-15 | 2016-09-20 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9486583B2 (en) | 2012-03-06 | 2016-11-08 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
US9522097B2 (en) | 2007-10-04 | 2016-12-20 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
US9561333B2 (en) | 2008-08-05 | 2017-02-07 | Antares Pharma, Inc. | Multiple dosage injector |
US9656016B2 (en) | 2014-01-29 | 2017-05-23 | Beckton, Dickinson And Company | Syringe packaging system including oxygen absorber |
US9707354B2 (en) | 2013-03-11 | 2017-07-18 | Antares Pharma, Inc. | Multiple dosage injector with rack and pinion dosage system |
US9744302B2 (en) | 2013-02-11 | 2017-08-29 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
EP3124005A4 (en) * | 2014-03-28 | 2017-10-25 | Terumo Kabushiki Kaisha | Packaged drug-filled container |
US9808582B2 (en) | 2006-05-03 | 2017-11-07 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9861555B2 (en) | 2004-10-13 | 2018-01-09 | Hyprotek, Inc. | Syringe devices and methods for mixing and administering medication |
US9867949B2 (en) | 2008-03-10 | 2018-01-16 | Antares Pharma, Inc. | Injector safety device |
US9950125B2 (en) | 2012-04-06 | 2018-04-24 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
US10213424B2 (en) | 2013-03-14 | 2019-02-26 | Fresenius Kabi Deutschland Gmbh | Morphine formulations |
US10214338B2 (en) | 2013-03-14 | 2019-02-26 | Fresenius Kabi Deutschland Gmbh | Packaging system for oxygen-sensitive drugs |
WO2019122368A1 (en) * | 2017-12-21 | 2019-06-27 | Inject Pharma Sweden Ab | Auto injector for oxygen reduced packaging |
WO2019122367A1 (en) * | 2017-12-21 | 2019-06-27 | Inject Pharma Sweden Ab | Auto injector set for oxygen reduced packaging |
WO2019139865A1 (en) * | 2018-01-10 | 2019-07-18 | Insys Development Company. Inc. | Methods of stabilizing epinephrine |
US10485930B2 (en) | 2005-11-09 | 2019-11-26 | Hyprotek, Inc. | Syringe devices, components of syringe devices, and methods of forming components and syringe devices |
US10906020B2 (en) | 2011-07-15 | 2021-02-02 | Cardinal Health 414, Llc | Systems, methods and devices for producing, manufacturing and control of radiopharmaceuticals |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544188B2 (en) * | 2001-07-19 | 2009-06-09 | Intelliject, Inc. | Medical injector |
US20030183545A1 (en) * | 2002-03-28 | 2003-10-02 | Carl Lauryssen | Surgical syringe holder |
SE522981C2 (en) * | 2002-07-01 | 2004-03-23 | Nobel Biocare Ab | Device and method for maintaining neoplastic effect of growth-stimulating substances in implant product |
US7329240B2 (en) * | 2003-01-02 | 2008-02-12 | Meridian Medical Technologies, Inc. | Protective packaging for medicament dispenser |
US7252651B2 (en) * | 2003-01-07 | 2007-08-07 | Becton, Dickinson And Company | Disposable injection device |
AU2004325202B2 (en) * | 2004-11-22 | 2009-02-19 | Kaleo, Inc. | Devices, systems, and methods for medicament delivery |
US7648482B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
US7648483B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US7947017B2 (en) | 2004-11-22 | 2011-05-24 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US7905352B2 (en) * | 2004-12-06 | 2011-03-15 | Washington Biotech Corporation | Kits containing medicine injection devices and containers |
WO2007008257A2 (en) * | 2005-07-06 | 2007-01-18 | Washington Biotech Corp. | Method and apparatus for delivering epinephrine |
US20110226646A1 (en) * | 2004-12-06 | 2011-09-22 | Wyrick Ronald E | Kits Containing Medicine Injection Devices And Containers |
US7297136B2 (en) * | 2004-12-06 | 2007-11-20 | Wyrick Ronald E | Medicine injection devices and methods |
DK2058020T3 (en) | 2005-02-01 | 2013-01-07 | Intelliject Inc | Device for administering drug |
US8361026B2 (en) | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
US7731686B2 (en) | 2005-02-01 | 2010-06-08 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US8226610B2 (en) * | 2005-02-01 | 2012-07-24 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
US8206360B2 (en) | 2005-02-01 | 2012-06-26 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
AT503142B1 (en) | 2006-01-18 | 2009-05-15 | Friedrich Ing Pipelka | CONTAINER FOR INTRODUCING AT LEAST ONE UNSTERILE VESSEL IN A STERILE AREA |
US20070169434A1 (en) * | 2006-01-26 | 2007-07-26 | Shawn Kinney | Process for aseptic vacuum filling and stoppering of low viscosity liquids in syringes |
TW200744568A (en) * | 2006-02-28 | 2007-12-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens |
WO2007143674A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies |
WO2007143676A2 (en) * | 2006-06-05 | 2007-12-13 | Verus Pharmaceuticals, Inc. | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
GB0619060D0 (en) * | 2006-09-27 | 2006-11-08 | Glaxosmithkline Biolog Sa | Novel process |
GB0700380D0 (en) | 2007-01-09 | 2007-02-14 | Breath Ltd | Storage Of Ampoules |
DE102007037565A1 (en) * | 2007-08-09 | 2009-02-12 | Mglas Ag | Syringe body and method for producing a syringe body |
US8002737B2 (en) * | 2007-10-04 | 2011-08-23 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
ES2430045T3 (en) * | 2007-12-19 | 2013-11-18 | Sanofi-Aventis Deutschland Gmbh | Two chamber syringe device with gas permeable membrane |
USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US8021344B2 (en) | 2008-07-28 | 2011-09-20 | Intelliject, Inc. | Medicament delivery device configured to produce an audible output |
JP6126783B2 (en) | 2009-03-02 | 2017-05-10 | セブンス センス バイオシステムズ,インコーポレーテッド | Device for analysis of a medium drawn from and / or under the skin of a subject |
US8366682B2 (en) | 2009-03-04 | 2013-02-05 | Washington Biotech Corporation | Medicine injection apparatuses |
GB2471304B (en) | 2009-06-24 | 2013-12-11 | Oval Medical Technologies Ltd | A pre-filled syringe or autoinjector |
GB2471726B (en) | 2009-07-10 | 2013-09-11 | Oval Medical Technologies Ltd | A pre-filled syringe including an oxygen absorber |
WO2011094573A1 (en) | 2010-01-28 | 2011-08-04 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
CA2695265A1 (en) * | 2010-03-02 | 2011-09-02 | Duoject Medical Systems Inc. | Injection device |
ES2896727T3 (en) * | 2010-03-25 | 2022-02-25 | New Injection Systems Ltd | Injector |
WO2011151315A1 (en) * | 2010-06-02 | 2011-12-08 | Sanofi-Aventis Deutschland Gmbh | Training cartridge for a drug delivery device |
EP2593014B1 (en) * | 2010-07-16 | 2015-11-04 | Seventh Sense Biosystems, Inc. | Low-pressure environment for fluid transfer devices |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9084849B2 (en) | 2011-01-26 | 2015-07-21 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9302799B2 (en) * | 2011-02-17 | 2016-04-05 | Sabic Global Technologies B.V. | Method for bulk transporting 2,6-xylenol susceptible to oxidative discoloration |
WO2012149126A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
EP3087919B2 (en) | 2011-04-29 | 2022-04-13 | Seventh Sense Biosystems, Inc. | Receiving fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
CN102895113A (en) * | 2011-07-28 | 2013-01-30 | 山东威高集团医用高分子制品股份有限公司 | Disposable protective drug dispenser |
SG192310A1 (en) | 2012-02-02 | 2013-08-30 | Becton Dickinson Holdings Pte Ltd | Adaptor for coupling to a medical container |
US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
CN103508089A (en) * | 2012-06-22 | 2014-01-15 | 康勇 | Method for packaging and storing traditional Chinese medicinal materials (including slices) |
JP2015521515A (en) * | 2012-07-02 | 2015-07-30 | ノボ ノルディスク ヘルス ケア アーゲー | Method for manufacturing a medical device |
CN104853787B (en) * | 2012-10-17 | 2018-06-19 | 椭元医疗技术有限公司 | Automatic drug conveying device |
US10471209B2 (en) | 2012-11-23 | 2019-11-12 | New Injection Systems Ltd. | Auto-injector assembly |
WO2014106056A2 (en) | 2012-12-27 | 2014-07-03 | Kaleo, Inc. | Devices, systems and methods for locating and interacting with medicament delivery systems |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
BR112017001442B1 (en) | 2014-08-04 | 2021-06-01 | Genentech, Inc | STOPPER AND METHOD OF LYOPHILLIZATION AND SEALING OF A MEDICINE |
AU2015357068B2 (en) * | 2014-12-03 | 2021-07-29 | Csl Behring Ag | Pharmaceutical product with increased stability comprising immunoglobulins |
JP6820104B2 (en) | 2014-12-08 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Versatile syringe base |
US9333289B1 (en) | 2015-01-16 | 2016-05-10 | Plas-Tech Engineering, Inc. | Tamper evident closure container |
CA2978090C (en) | 2015-03-02 | 2023-12-12 | Fresenius Kabi Austria Gmbh | Plunger rod comprising at least three annular elements for a prefilled syringe |
CN204446847U (en) * | 2015-03-03 | 2015-07-08 | 苏州同力生物医药有限公司 | A kind of disposable per nasal brain-targeted drug delivery device |
CN204446845U (en) * | 2015-03-03 | 2015-07-08 | 苏州同力生物医药有限公司 | A kind of disposable per nasal brain-targeted drug delivery device |
CN204446846U (en) * | 2015-03-03 | 2015-07-08 | 苏州同力生物医药有限公司 | A kind of disposable per nasal brain-targeted drug delivery device |
CN104667391B (en) * | 2015-03-03 | 2017-08-25 | 苏州同力生物医药有限公司 | A kind of disposable intranasal brain-targeted drug delivery device |
AU2016235054B2 (en) | 2015-03-24 | 2020-07-16 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
EP3316928B1 (en) | 2015-06-30 | 2022-10-19 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
CN105151342A (en) * | 2015-07-15 | 2015-12-16 | 广州金中健医疗器材有限公司 | Packing method and device for propofol injections |
CZ306565B6 (en) * | 2015-11-20 | 2017-03-08 | ChemProtect.SK s.r.o. | An autoinjector |
GB2547896A (en) * | 2016-02-28 | 2017-09-06 | Harrison Richard | Closure member with septum |
CN106176215A (en) * | 2016-06-28 | 2016-12-07 | 宋占涛 | A kind of clamped bottle goods drying property and the keeping method of stability |
US10688244B2 (en) | 2016-12-23 | 2020-06-23 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10332623B2 (en) | 2017-01-17 | 2019-06-25 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and event detection |
US11083712B1 (en) | 2018-03-20 | 2021-08-10 | Relevale, Inc. | Low concentration delivery of an ergoline derivative for treatment of a headache |
WO2019209260A1 (en) * | 2018-04-24 | 2019-10-31 | W. L. Gore & Associates, Inc. | Medical delivery devices with inhibited oxygen permeation |
US11929160B2 (en) | 2018-07-16 | 2024-03-12 | Kaleo, Inc. | Medicament delivery devices with wireless connectivity and compliance detection |
US11021312B2 (en) * | 2018-12-21 | 2021-06-01 | Altria Client Services Llc | Pouch with oxygen scavenger and method of forming pouch with oxygen scavenger |
KR102083549B1 (en) * | 2019-03-19 | 2020-03-02 | 조아제약주식회사 | Vial to be sealed and filled with liquid |
US20220304893A1 (en) * | 2019-06-17 | 2022-09-29 | Beloteca, Inc. | Protection of oxygen sensitive compounds |
EP4009936A4 (en) | 2019-08-09 | 2023-08-09 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2735799A (en) * | 1956-02-21 | Epinephrine ointment and method of | ||
US3540444A (en) * | 1968-01-15 | 1970-11-17 | Scherer Corp R P | Plastic ampoule for use with hypodermic injector |
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
US4394863A (en) * | 1981-10-23 | 1983-07-26 | Survival Technology, Inc. | Automatic injector with cartridge having separate sequentially injectable medicaments |
US4553962A (en) * | 1983-01-17 | 1985-11-19 | Brunet Jean Louis | Medical syringe |
US4869398A (en) * | 1986-11-25 | 1989-09-26 | Life Technologies, Inc. | Liquid container delivery and storage system |
US4872553A (en) * | 1986-03-22 | 1989-10-10 | Material Engineering Technology Laboratory, Incorporated | Medical fluid-filled plastic container and methods of making same |
US5334162A (en) * | 1993-03-15 | 1994-08-02 | Eli Lilly And Company | Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same |
US5354286A (en) * | 1993-12-07 | 1994-10-11 | Survival Technology, Inc. | Injection device having polyparaxylylene coated container |
US5364369A (en) * | 1987-07-08 | 1994-11-15 | Reynolds David L | Syringe |
US5383864A (en) * | 1989-03-28 | 1995-01-24 | Duphar International Research B.V. | Pre-filled injection device comprising a barrel wherein a liquid diazepam formulation is accommodated |
US5483973A (en) * | 1992-10-30 | 1996-01-16 | Becton, Dickinson And Company | Needle stopper and needle removal device |
US5531683A (en) * | 1992-08-13 | 1996-07-02 | Science Incorporated | Mixing and delivery syringe assembly |
US5569236A (en) * | 1989-06-16 | 1996-10-29 | Science Incorporated | Fluid delivery apparatus |
US5586975A (en) * | 1994-02-18 | 1996-12-24 | Takeda Chemical Industries. Ltd. | Air and liquid tight container with a slidable gasket |
US5605542A (en) * | 1992-04-30 | 1997-02-25 | Takeda Chemical Industries, Ltd. | Prefilled syringe |
US5620423A (en) * | 1993-09-23 | 1997-04-15 | Heraeus Kulzer Gmbh | Syringe for the controlled discharge of viscous materials |
US5654054A (en) * | 1992-12-18 | 1997-08-05 | Becton, Dickinson And Company | Barrier coating |
US5723189A (en) * | 1991-07-22 | 1998-03-03 | Daikyo Gomu Seiko Ltd. | Container for a sanitary article |
US5749968A (en) * | 1993-03-01 | 1998-05-12 | Focal, Inc. | Device for priming for improved adherence of gels to substrates |
US5782815A (en) * | 1995-01-26 | 1998-07-21 | Yuji Yanai | Glass cartridge for injection syringe prefilled with pharmaceutical liquid |
US5833653A (en) * | 1996-09-23 | 1998-11-10 | Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg | Prefilled hypodermic syringe |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US5939425A (en) * | 1996-10-09 | 1999-08-17 | Algos Pharmaceutical Corporation | Method for treating a migraine |
US6210369B1 (en) * | 1997-12-16 | 2001-04-03 | Meridian Medical Technologies Inc. | Automatic injector |
US6315112B1 (en) * | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
US6620135B1 (en) * | 1998-08-19 | 2003-09-16 | Weston Medical Limited | Needleless injectors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US535286A (en) * | 1895-03-05 | Wrist-plate hook-rod | ||
DE10018471A1 (en) * | 2000-04-14 | 2001-10-25 | Braun Melsungen Ag | Material that absorbs oxygen and hydrogen sulfide |
-
2002
- 2002-11-01 CA CA002465436A patent/CA2465436A1/en not_active Abandoned
- 2002-11-01 MX MXPA04004162A patent/MXPA04004162A/en active IP Right Grant
- 2002-11-01 WO PCT/US2002/035033 patent/WO2003039632A2/en active Application Filing
- 2002-11-01 JP JP2003541921A patent/JP2005508231A/en active Pending
- 2002-11-01 KR KR1020047006508A patent/KR20050042210A/en not_active Application Discontinuation
- 2002-11-01 EP EP02784368A patent/EP1455864A2/en not_active Withdrawn
- 2002-11-01 CN CNA028259211A patent/CN1607968A/en active Pending
- 2002-11-01 US US10/285,692 patent/US7708719B2/en active Active
- 2002-11-01 IL IL16168202A patent/IL161682A0/en unknown
- 2002-11-01 AU AU2002348148A patent/AU2002348148B2/en not_active Ceased
-
2008
- 2008-01-23 AU AU2008200344A patent/AU2008200344A1/en not_active Abandoned
-
2010
- 2010-03-17 US US12/725,518 patent/US20100174268A1/en not_active Abandoned
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2735799A (en) * | 1956-02-21 | Epinephrine ointment and method of | ||
US3540444A (en) * | 1968-01-15 | 1970-11-17 | Scherer Corp R P | Plastic ampoule for use with hypodermic injector |
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
US4394863A (en) * | 1981-10-23 | 1983-07-26 | Survival Technology, Inc. | Automatic injector with cartridge having separate sequentially injectable medicaments |
US4553962A (en) * | 1983-01-17 | 1985-11-19 | Brunet Jean Louis | Medical syringe |
US4872553A (en) * | 1986-03-22 | 1989-10-10 | Material Engineering Technology Laboratory, Incorporated | Medical fluid-filled plastic container and methods of making same |
US4869398A (en) * | 1986-11-25 | 1989-09-26 | Life Technologies, Inc. | Liquid container delivery and storage system |
US5364369A (en) * | 1987-07-08 | 1994-11-15 | Reynolds David L | Syringe |
US5383864A (en) * | 1989-03-28 | 1995-01-24 | Duphar International Research B.V. | Pre-filled injection device comprising a barrel wherein a liquid diazepam formulation is accommodated |
US5569236A (en) * | 1989-06-16 | 1996-10-29 | Science Incorporated | Fluid delivery apparatus |
US5720729A (en) * | 1989-06-16 | 1998-02-24 | Science Incorporated | Fluid delivery apparatus |
US5723189A (en) * | 1991-07-22 | 1998-03-03 | Daikyo Gomu Seiko Ltd. | Container for a sanitary article |
US5716339A (en) * | 1992-04-30 | 1998-02-10 | Takeda Chemical Industries, Ltd. | Prefilled syringe |
US5865799A (en) * | 1992-04-30 | 1999-02-02 | Takeda Chemical Industries | Prefilled syringe |
US5605542A (en) * | 1992-04-30 | 1997-02-25 | Takeda Chemical Industries, Ltd. | Prefilled syringe |
US5817056A (en) * | 1992-04-30 | 1998-10-06 | Takeda Chemical Industries, Ltd. | Prefilled syringe |
US5531683A (en) * | 1992-08-13 | 1996-07-02 | Science Incorporated | Mixing and delivery syringe assembly |
US5483973A (en) * | 1992-10-30 | 1996-01-16 | Becton, Dickinson And Company | Needle stopper and needle removal device |
US5654054A (en) * | 1992-12-18 | 1997-08-05 | Becton, Dickinson And Company | Barrier coating |
US5749968A (en) * | 1993-03-01 | 1998-05-12 | Focal, Inc. | Device for priming for improved adherence of gels to substrates |
US5334162A (en) * | 1993-03-15 | 1994-08-02 | Eli Lilly And Company | Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same |
US5620423A (en) * | 1993-09-23 | 1997-04-15 | Heraeus Kulzer Gmbh | Syringe for the controlled discharge of viscous materials |
US5354286A (en) * | 1993-12-07 | 1994-10-11 | Survival Technology, Inc. | Injection device having polyparaxylylene coated container |
US5586975A (en) * | 1994-02-18 | 1996-12-24 | Takeda Chemical Industries. Ltd. | Air and liquid tight container with a slidable gasket |
US5782815A (en) * | 1995-01-26 | 1998-07-21 | Yuji Yanai | Glass cartridge for injection syringe prefilled with pharmaceutical liquid |
US5833653A (en) * | 1996-09-23 | 1998-11-10 | Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg | Prefilled hypodermic syringe |
US5939425A (en) * | 1996-10-09 | 1999-08-17 | Algos Pharmaceutical Corporation | Method for treating a migraine |
US6043244A (en) * | 1996-10-09 | 2000-03-28 | Algos Pharmaceutical Corporation | Method and composition for treating migraine |
US5855907A (en) * | 1997-03-24 | 1999-01-05 | Peyman; Gholam A. | Method of treatment of migraine |
US6210369B1 (en) * | 1997-12-16 | 2001-04-03 | Meridian Medical Technologies Inc. | Automatic injector |
US6620135B1 (en) * | 1998-08-19 | 2003-09-16 | Weston Medical Limited | Needleless injectors |
US6315112B1 (en) * | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737670B2 (en) | 2002-02-11 | 2017-08-22 | Antares Pharma, Inc. | Intradermal injector |
US9333309B2 (en) | 2002-02-11 | 2016-05-10 | Antares Pharma, Inc. | Intradermal injector |
US11376195B2 (en) | 2004-10-13 | 2022-07-05 | Hyprotek, Inc. | Syringe devices and methods for mixing and administering medication |
US9861555B2 (en) | 2004-10-13 | 2018-01-09 | Hyprotek, Inc. | Syringe devices and methods for mixing and administering medication |
US11446441B2 (en) | 2005-01-24 | 2022-09-20 | Antares Pharma, Inc. | Prefilled syringe injector |
US9180259B2 (en) | 2005-01-24 | 2015-11-10 | Antares Pharma, Inc. | Prefilled syringe jet injector |
US9629959B2 (en) | 2005-01-24 | 2017-04-25 | Antares Pharma, Inc. | Prefilled syringe jet injector |
US10478560B2 (en) | 2005-01-24 | 2019-11-19 | Antares Pharma, Inc. | Prefilled syringe injector |
US10485930B2 (en) | 2005-11-09 | 2019-11-26 | Hyprotek, Inc. | Syringe devices, components of syringe devices, and methods of forming components and syringe devices |
US11547808B2 (en) | 2006-05-03 | 2023-01-10 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9808582B2 (en) | 2006-05-03 | 2017-11-07 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US10688250B2 (en) | 2006-05-03 | 2020-06-23 | Antares Pharma, Inc. | Two-stage reconstituting injector |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
US10543316B2 (en) | 2006-05-03 | 2020-01-28 | Antares Pharma, Inc. | Injector with adjustable dosing |
US11471600B2 (en) | 2006-05-03 | 2022-10-18 | Antares Pharma, Inc. | Injector with adjustable dosing |
US10524983B2 (en) | 2007-10-04 | 2020-01-07 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
US9522097B2 (en) | 2007-10-04 | 2016-12-20 | Hyprotek, Inc. | Mixing/administration syringe devices, protective packaging and methods of protecting syringe handlers |
US11684723B2 (en) | 2008-03-10 | 2023-06-27 | Antares Pharma, Inc. | Injector safety device |
US9867949B2 (en) | 2008-03-10 | 2018-01-16 | Antares Pharma, Inc. | Injector safety device |
US10709844B2 (en) | 2008-03-10 | 2020-07-14 | Antares Pharma, Inc. | Injector safety device |
US10300212B2 (en) | 2008-08-05 | 2019-05-28 | Antares Pharma, Inc. | Multiple dosage injector |
US11058824B2 (en) | 2008-08-05 | 2021-07-13 | Antares Pharma, Inc. | Multiple dosage injector |
US9561333B2 (en) | 2008-08-05 | 2017-02-07 | Antares Pharma, Inc. | Multiple dosage injector |
US9750881B2 (en) | 2009-03-20 | 2017-09-05 | Antares Pharma, Inc. | Hazardous agent injection system |
US10555954B2 (en) | 2009-03-20 | 2020-02-11 | Antares Pharma, Inc. | Hazardous agent injection system |
US11497753B2 (en) | 2009-03-20 | 2022-11-15 | Antares Pharma, Inc. | Hazardous agent injection system |
US8945063B2 (en) | 2009-03-20 | 2015-02-03 | Antares Pharma, Inc. | Hazardous agent injection system |
US10226401B2 (en) * | 2010-12-29 | 2019-03-12 | Cardinal Health 414, Llc | Closed vial fill system for aseptic dispensing |
US20160199257A1 (en) * | 2010-12-29 | 2016-07-14 | Cardinal Health 414, Llc | Closed vial fill system for aseptic dispensing |
US8616879B2 (en) | 2011-03-22 | 2013-12-31 | Centrix, Inc. | Capsule and delivery tip with transition portion for dispensing viscous reactive dental materials |
US10906020B2 (en) | 2011-07-15 | 2021-02-02 | Cardinal Health 414, Llc | Systems, methods and devices for producing, manufacturing and control of radiopharmaceuticals |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US10568809B2 (en) | 2011-07-15 | 2020-02-25 | Ferring B.V. | Liquid-transfer adapter beveled spike |
US11185642B2 (en) | 2011-07-15 | 2021-11-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US10279131B2 (en) | 2011-07-15 | 2019-05-07 | Antares Pharma, Inc. | Injection device with cammed RAM assembly |
US9446195B2 (en) | 2011-07-15 | 2016-09-20 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US10391250B2 (en) | 2011-09-30 | 2019-08-27 | Becton Dickinson France, S.A.S. | Attachable plunger rod and associated packaging |
US9333288B2 (en) | 2011-09-30 | 2016-05-10 | Becton Dickinson France, S.A.S. | Attachable plunger rod and associated packaging |
US11602597B2 (en) | 2012-03-06 | 2023-03-14 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
US10478559B2 (en) | 2012-03-06 | 2019-11-19 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
US9486583B2 (en) | 2012-03-06 | 2016-11-08 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
US11771646B2 (en) | 2012-04-06 | 2023-10-03 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
US9950125B2 (en) | 2012-04-06 | 2018-04-24 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
US10821072B2 (en) | 2012-04-06 | 2020-11-03 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
US10357609B2 (en) | 2012-05-07 | 2019-07-23 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US10905827B2 (en) | 2012-05-07 | 2021-02-02 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9364610B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
US9364611B2 (en) | 2012-05-07 | 2016-06-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US11446440B2 (en) | 2012-05-07 | 2022-09-20 | Antares Pharma, Inc. | Needle assisted injection device having reduced trigger force |
US9744302B2 (en) | 2013-02-11 | 2017-08-29 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
US10881798B2 (en) | 2013-02-11 | 2021-01-05 | Antares Pharma, Inc. | Needle assisted injection device having reduced trigger force |
US11813435B2 (en) | 2013-02-11 | 2023-11-14 | Antares Pharma, Inc. | Needle assisted injection device having reduced trigger force |
US9707354B2 (en) | 2013-03-11 | 2017-07-18 | Antares Pharma, Inc. | Multiple dosage injector with rack and pinion dosage system |
US11628260B2 (en) | 2013-03-11 | 2023-04-18 | Antares Pharma, Inc. | Multiple dosage injector with rack and pinion dosage system |
US10610649B2 (en) | 2013-03-11 | 2020-04-07 | Antares Pharma, Inc. | Multiple dosage injector with rack and pinion dosage system |
US10675400B2 (en) | 2013-03-12 | 2020-06-09 | Antares Pharma, Inc. | Prefilled syringes and kits thereof |
US9393367B2 (en) | 2013-03-12 | 2016-07-19 | Antares Pharma, Inc. | Prefilled syringes and kits thereof |
US10213424B2 (en) | 2013-03-14 | 2019-02-26 | Fresenius Kabi Deutschland Gmbh | Morphine formulations |
US11214426B2 (en) | 2013-03-14 | 2022-01-04 | Fresenius Kabi Deutschland Gmbh | Packaging system for oxygen-sensitive drugs |
US10214338B2 (en) | 2013-03-14 | 2019-02-26 | Fresenius Kabi Deutschland Gmbh | Packaging system for oxygen-sensitive drugs |
US10781027B2 (en) | 2013-03-14 | 2020-09-22 | Fresenius Kabi Deutschland Gmbh | Packaging system for oxygen-sensitive drugs |
US10286142B2 (en) | 2014-01-29 | 2019-05-14 | Becton, Dickinson And Company | Syringe packaging system including oxygen absorber |
US9656016B2 (en) | 2014-01-29 | 2017-05-23 | Beckton, Dickinson And Company | Syringe packaging system including oxygen absorber |
US10076603B2 (en) | 2014-01-29 | 2018-09-18 | Becton, Dickinson And Company | Syringe packaging system including oxygen absorber |
US10329073B2 (en) | 2014-03-28 | 2019-06-25 | Terumo Kabushiki Kaisha | Packaged medicine-filled container |
US10065784B2 (en) | 2014-03-28 | 2018-09-04 | Terumo Kabushiki Kaisha | Packaged medicine-filled container |
EP3124005A4 (en) * | 2014-03-28 | 2017-10-25 | Terumo Kabushiki Kaisha | Packaged drug-filled container |
WO2019122367A1 (en) * | 2017-12-21 | 2019-06-27 | Inject Pharma Sweden Ab | Auto injector set for oxygen reduced packaging |
US11504474B2 (en) * | 2017-12-21 | 2022-11-22 | Inject Pharma Sweden Ab | Auto injector for oxygen reduced packaging |
WO2019122368A1 (en) * | 2017-12-21 | 2019-06-27 | Inject Pharma Sweden Ab | Auto injector for oxygen reduced packaging |
US11077075B2 (en) | 2018-01-10 | 2021-08-03 | Hikma Pharmaceuticals Usa Inc. | Methods of stabilizing epinephrine |
US11744811B2 (en) | 2018-01-10 | 2023-09-05 | Hikma Pharmaceuticals Usa Inc. | Methods of stabilizing epinephrine |
WO2019139865A1 (en) * | 2018-01-10 | 2019-07-18 | Insys Development Company. Inc. | Methods of stabilizing epinephrine |
Also Published As
Publication number | Publication date |
---|---|
KR20050042210A (en) | 2005-05-06 |
WO2003039632A2 (en) | 2003-05-15 |
AU2002348148B2 (en) | 2008-07-10 |
JP2005508231A (en) | 2005-03-31 |
IL161682A0 (en) | 2004-09-27 |
US20030106824A1 (en) | 2003-06-12 |
EP1455864A2 (en) | 2004-09-15 |
CN1607968A (en) | 2005-04-20 |
US7708719B2 (en) | 2010-05-04 |
AU2008200344A1 (en) | 2008-02-14 |
WO2003039632A3 (en) | 2003-11-20 |
CA2465436A1 (en) | 2003-05-15 |
MXPA04004162A (en) | 2005-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7708719B2 (en) | Medicament container, a medicament dispensing kit for administering medication and a method for packaging the same | |
AU2002348148A1 (en) | A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same | |
US8679068B2 (en) | Pre-filled syringe including an oxygen absorber | |
US10780227B2 (en) | Pre-filled syringe or autoinjector | |
US6866142B2 (en) | Pre-filled package containing unit dose of medical gas and method of making the same | |
KR20110129400A (en) | Drug container and delivery mechanism | |
US20240009380A1 (en) | Manufacturing method for packaged medicine administering device | |
US11504474B2 (en) | Auto injector for oxygen reduced packaging | |
WO2019063785A1 (en) | Prefilled syringe and method of preparing a prefilled syringe | |
WO2011125562A1 (en) | Prefilled syringe and method for assembling prefilled syringe | |
US20210346615A1 (en) | Devices and methods for delivering a substance to a body cavity utilizing blow-fill-seal technology | |
WO2021260631A1 (en) | Devices and methods for delivering a substance to a body cavity utilizing blow-fill-seal technology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERIDIAN MEDICAL TECHNOLOGIES, INC., MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILMOT, JOHN G.;MESA, MICHAEL C.;SIGNING DATES FROM 20030102 TO 20030127;REEL/FRAME:024090/0480 |
|
AS | Assignment |
Owner name: CREDIT SUISSE AG, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024379/0816 Effective date: 20100511 |
|
AS | Assignment |
Owner name: MERIDIAN MEDICAL TECHNOLOGIES, INC., MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG;REEL/FRAME:025741/0482 Effective date: 20110131 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |